Sat.Mar 09, 2024 - Fri.Mar 15, 2024

article thumbnail

2024 predictions: Experts comment on monoclonal antibodies 

Drug Discovery World

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates.

article thumbnail

Scientists generate new targeted protein degradation system that tunes a cell’s own proteins

Broad Institute

Scientists generate new targeted protein degradation system that tunes a cell’s own proteins By Leah Eisenstadt March 14, 2024 Breadcrumb Home Scientists generate new targeted protein degradation system that tunes a cell’s own proteins Researchers have engineered a compact degron tag that can be precisely edited into a cell’s genome, enabling scientists to trigger the rapid breakdown of native target proteins.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Madrigal wins FDA approval of first drug for MASH

BioPharma Drive: Drug Pricing

Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.

article thumbnail

Milk to the rescue for diabetics? Cow produces human insulin in milk

Science Daily: Pharmacology News

An unassuming brown bovine from the south of Brazil has made history as the first transgenic cow capable of producing human insulin in her milk. The advancement could herald a new era in insulin production, one day eliminating drug scarcity and high costs for people living with diabetes.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Can Singapore become a global hub for biotech?

Drug Discovery World

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. Thanks to significant investment by the government into research and development, Singapore has become a leading centre for biomedical sciences in Asia.

article thumbnail

What do volunteers for research studies do after finding a trial?

Antidote

For many people, participating in a research study presents an interesting opportunity with many benefits to volunteering. While there are many types of clinical research, all with distinct goals and timelines, trial volunteers will follow a similar path when taking part. Read on to learn more about the process.

Trials 119

More Trending

article thumbnail

A healthier diet is linked with a slower pace of aging, reduced dementia risk, study shows

Science Daily: Pharmacology News

A healthier diet is associated with a reduced dementia risk and slower pace of aging, according to a new study. The findings show that a diet-dementia association was at least partially facilitated by multi-system processes of aging. Until now, the biological mechanism of this protection was not well understood.

125
125
article thumbnail

Orphan Drug Designation for first-in-class autotaxin cancer therapy

Drug Discovery World

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring certain benefits during development and commercialisation.

Therapies 173
article thumbnail

Zepbound Helps Obese People Shed Pounds, Regardless of Starting Weight

Drugs.com

THURSDAY, March 14, 2024 -- The blockbuster weight-loss medication Zepbound (tirzepatide) appears to help folks quickly shed pounds regardless of how overweight they are, or how long they've lived being overweight or obese. Those are the findings.

116
116
article thumbnail

Madrigal, FDA approval in hand, outlines plan to sell MASH drug

BioPharma Drive: Drug Pricing

The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

7 things to know about multiple sclerosis

Antidote

Receiving a multiple sclerosis (MS) diagnosis can feel overwhelming and isolating for many. MS is a neurodegenerative disease that often involves challenging symptoms — but knowing what to expect and what resources are available can help.

Disease 116
article thumbnail

Two wins for vaccine company at Scotland’s Life Sciences Awards

Drug Discovery World

Valneva Scotland scooped two prizes at Scotland’s Life Sciences Awards 2024, including the award for Innovation – Pharma Services And Drug Discovery, in a ceremony on 14 March in Glasgow. Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 147
article thumbnail

Vitamin D Plus Calcium: Good News, Bad News for Older Women

Drugs.com

TUESDAY, March 12, 2024 -- Women who've gone through menopause and hope that supplemental vitamin D plus calcium might shield them from disease may be disappointed by new data.A follow-up analysis of data from the landmark Women's Health Initiative.

Disease 116
article thumbnail

After surprise trial failure, ALS doctors brace for one less treatment option

BioPharma Drive: Drug Pricing

Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.

Doctors 122
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

An electricity generator inspired by the drinking bird toy powers electronics with evaporated water

Science Daily: Pharmacology News

Inspired by the classic drinking bird toy, scientists have developed an engine that efficiently converts energy from water evaporation into electricity to power small electronics. The device produces energy outputs exceeding 100 volts -- much higher than other techniques that generate electricity from water -- and can operate for several days using only 100 milliliters of water as fuel, according to a new study.

article thumbnail

Tackling pain and mental health with plant-based medicines

Drug Discovery World

DDW Editor Reece Armstrong speaks to Michael Krogh Jensen , Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. RA: How has being part of the Bio Studio programme helped you develop your pipeline? MJ : The Bio Studio programme has offered Biomia a ‘cloud’ of key opinion leaders providing constructive feedback and authoritative direction on our technology, working hypothesis, business mod

article thumbnail

Poor Trial Results May Prompt Maker to Pull ALS Drug, Relyvrio, From Market

Drugs.com

MONDAY, March 11, 2024 -- Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. In a statement issued Friday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a.

Marketing 115
article thumbnail

German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

BioPharma Drive: Drug Pricing

The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.

Drugs 123
article thumbnail

Drought, soil desiccation cracking, and carbon dioxide emissions: an overlooked feedback loop exacerbating climate change

Science Daily: Pharmacology News

Soil stores 80 percent of carbon on earth, yet with increasing cycles of drought, that crucial reservoir is cracking and breaking down, releasing even more greenhouse gases creating an amplified feedback loop that could accelerate climate change.

115
115
article thumbnail

New DDW Highlights podcast: 11 March 2024

Drug Discovery World

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and the announcement that the FDA will delay approval of donanemab to hold

FDA 147
article thumbnail

Four Key Takeaways from TrailblazerDX

Perficient: Drug Development

Last week, I attended TrailblazerDX in San Francisco, where the content was all about Salesforce Data Cloud and AI! There were over 300 sessions to attend, from technical talks to hands-on workshops where attendees could learn how to build copilots and how to use the latest Salesforce platform features directly from product managers , architects, and fellow developers.

article thumbnail

Amylyx CEOs look for a path forward following major setback

BioPharma Drive: Drug Pricing

Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.

article thumbnail

Alaska dinosaur tracks reveal a lush, wet environment

Science Daily: Pharmacology News

A large find of dinosaur tracks and fossilized plants and tree stumps in far northwestern Alaska provides new information about the climate and movement of animals near the time when they began traveling between the Asian and North American continents roughly 100 million years ago.

115
115
article thumbnail

Elsevier and Iktos partner to launch AI-powered drug discovery database

Drug Discovery World

Elsevier and Iktos have partnered to strengthen Elsevier’s chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos. The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing the length and cost of early-stage drug discovery.

article thumbnail

Precautions Needed When Folks Taking Ozempic, Wegovy Undergo Anesthesia

Drugs.com

WEDNESDAY, March 13, 2024 — Nurses who specialize in anesthesia have issued new guidelines to reduce the risk that patients taking weight-loss drugs like Ozempic or Wegovy throw up during surgery."These medications have exploded in.

Nurses 111
article thumbnail

BIO changes stance, backs bill to limit China’s role in US biotech

BioPharma Drive: Drug Pricing

Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with Wuxi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

114
114
article thumbnail

A new world of 2D material is opening up

Science Daily: Pharmacology News

Materials that are incredibly thin, only a few atoms thick, exhibit unique properties that make them appealing for energy storage, catalysis and water purification. Researchers have now developed a method that enables the synthesis of hundreds of new 2D materials.

Research 112
article thumbnail

This week in drug discovery (11-15 March) 

Drug Discovery World

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. The top stories: New drug shows promising neuroprotective effects Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and

article thumbnail

#ScienceSaturday: March 9, 2024

KIF1A

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Meet our Guest Bloggers! This spring we’ve been quite fortunate to be joined by 6 Master’s students from Columbia University, who have been contributing to our creation of community resources as part of the

article thumbnail

Boehringer, Sosei Heptares team up in schizophrenia drug deal

BioPharma Drive: Drug Pricing

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 111
article thumbnail

Bile acids and the microbiome: revolutionising disease approaches

Drug Target Review

Scientists from the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego have discovered thousands of bile acids. The study’s findings offer new insights into the biochemical language microbes use to influence distant organ systems, which could revolutionise the way researchers approach disease. Dr Pieter Dorrestein, senior author, professor at the Skaggs School and professor of pharmacology and paediatrics at UC San Diego School of Medicine, stated: “B

Disease 109
article thumbnail

Early trial data supports neurodegenerative disease-modifying drug

Drug Discovery World

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon. The Phase Ib study examined the safety, tolerability and pharmacokinetics of twice-daily oral doses of ALX-001 in 32 heathy adult participants aged 50-80.

Disease 130
article thumbnail

Supply chain disruptions will further exacerbate economic losses from climate change

Science Daily: Pharmacology News

Global GDP loss from climate change will increase exponentially the warmer the planet gets when its cascading impact on global supply chains is factored in, finds a new study.

108
108
article thumbnail

Use of Legal 'Delta-8-THC' Is Rising Among Teens - Is it Safe?

Drugs.com

TUESDAY, March 12, 2024 -- They're cheap, easy to buy and now new research shows they have become the buzz of choice for American teens. Delta-8-THC products, which include gummies and vapes, are legal in 22 states and Washington, D.C. There is no.